<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet12109</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-12109</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзор литературы</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Влияние хирургического лечения ожирения на пуриновый обмен и подагру</article-title><trans-title-group xml:lang="en"><trans-title>The effect of bariatric surgery on purine metabolism and gout</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5290-156X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Паневин</surname><given-names>Тарас Сергеевич</given-names></name><name name-style="western" xml:lang="en"><surname>Panevin</surname><given-names>Taras S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-эндокринолог отделения специализированной медицинской помощи; врач-ревматолог консультативно-диагностического центра; врач-ревматолог 2 терапевтического отделения </p></bio><bio xml:lang="en"><p>endocrinologist of the department of specialized medical care; rheumatologist at the Consultative and Diagnostic Center; rheumatologist of the 2nd therapeutic department</p></bio><email xlink:type="simple">tarasel@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1191-5831</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елисеев</surname><given-names>Максим Сергеевич</given-names></name><name name-style="western" xml:lang="en"><surname>Eliseev</surname><given-names>Maxim S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., заведующий лабораторией микрокристаллических артритов ФГБНУ НИИР им. В.А. Насоновой</p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">elicmax@rambler.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5057-127X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестакова</surname><given-names>Марина Владимировна</given-names></name><name name-style="western" xml:lang="en"><surname>Shestakova</surname><given-names>Marina V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН</p></bio><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><email xlink:type="simple">shestakova.mv@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт ревматологии им. В.А. Насоновой; Национальный медицинский исследовательский центр эндокринологии; Консультативно-диагностический центр Генерального штаба Вооруженных сил Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; Endocrinology Research Centre; Advisory and Diagnostic center of the General Staff of the Armed Forces of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт ревматологии им. В.А. Насоновой</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр эндокринологии Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>21</day><month>09</month><year>2020</year></pub-date><volume>17</volume><issue>2</issue><fpage>138</fpage><lpage>146</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Паневин Т.С., Елисеев М.С., Шестакова М.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Паневин Т.С., Елисеев М.С., Шестакова М.В.</copyright-holder><copyright-holder xml:lang="en">Panevin T.S., Eliseev M.S., Shestakova M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/12109">https://www.omet-endojournals.ru/jour/article/view/12109</self-uri><abstract><p>Подагра является системным аутовоспалительным тофусным заболеванием и характеризуется отложением кристаллов моноурата натрия (МУН) с последующим развитием воспаления у лиц с гиперурикемией (ГУ). Помимо генетических, факторами риска развития ГУ и подагры являются многие модифицируемые факторы, среди которых метаболический синдром и ожирение, а их коррекция – важнейшая составляющая успешного контроля над заболеванием. Ожирение может изменять клиническую картину подагры, характеризующуюся более ранним началом и бо́льшим числом пораженных суставов. Потеря веса способствует снижению уровня мочевой кислоты (МК) сыворотки. Бариатрическая/метаболическая хирургия значительно сокращает частоту развития коморбидных ожирению состояний и смертность и на сегодняшний день является наиболее эффективным методом борьбы с ожирением. Помимо улучшения состояния здоровья, важная цель бариатрической хирургии – повысить качество жизни. Бариатрические операции могут предотвращать развитие ГУ у субъектов с исходно нормальным уровнем сывороточной МК до оперативного вмешательства. Динамика концентрации МК в сыворотке крови может быть предиктором успешно проведенного бариатрического лечения и помочь в прогнозировании выраженности послеоперационной потери веса. Снижение массы тела после проведения бариатрических операций приводит к уменьшению МК в отдаленном периоде, однако наблюдается высокая частота острых приступов подагры в раннем послеоперационном периоде. Таким образом, бариатрическая хирургия оказывает значимое влияние на ГУ и подагру и может быть эффективным методом лечения данного заболевания.</p></abstract><trans-abstract xml:lang="en"><p>Gout is an auto-inflammatory tophaceous disease characterized by the deposition of crystals of monosodium urate and developing in connection with this inflammation in people with hyperuricemia (HU). Except to genetic factors, risk factors for the development of HU and gout are many modifiable factors, including metabolic syndrome and obesity, and their correction is the most important component of successful disease control. Obesity can change the clinical picture of gout, characterized by an earlier onset, a large number of affected joints. Weight loss helps reduce uric acid (UA) serum levels. Bariatric / metabolic surgery significantly reduces the incidence of comorbid obesity and mortality, and is by far the most effective way to combat obesity. In addition to improving health, an important goal of bariatric surgery is to improve the quality of life. Bariatric surgery can prevent the development of HU in subjects with an initially normal level of serum UA before surgery. The dynamics of the concentration of UA in serum can be a predictor of successful bariatric surgery and help in predicting the severity of postoperative weight loss. The decrease in body weight after bariatric surgery leads to a decrease in UA in the long-term postoperative period, however, there is a high frequency of acute gout attacks in the early postoperative period. Thus, bariatric surgery has a significant effect on HU and gout and can be an effective treatment for this disease.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>подагра</kwd><kwd>гиперурикемия</kwd><kwd>мочевая кислота</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>бариатрическая хирургия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>gout</kwd><kwd>hyperuricemia</kwd><kwd>uric acid</kwd><kwd>type 2 diabetes</kwd><kwd>bariatric surgery</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. // Научно-практическая ревматология. — 2004. — Т. 42. — №1. — С. 5-7. [Nasonova VA, Barskova VG. Early diagnostic and treatment of gout – is scientifically based reguirements for improvement of labour and living prognosis of patients. Rheumatology Science and Practice. 2004;42(1):5-7. (In Russ.)] DOI:10.14412/1995-4484-2004-1374</mixed-citation><mixed-citation xml:lang="en">Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. // Научно-практическая ревматология. — 2004. — Т. 42. — №1. — С. 5-7. [Nasonova VA, Barskova VG. Early diagnostic and treatment of gout – is scientifically based reguirements for improvement of labour and living prognosis of patients. Rheumatology Science and Practice. 2004;42(1):5-7. (In Russ.)] DOI:10.14412/1995-4484-2004-1374</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е.Л., Елисеев М.С. Роль интерлейкина 1 в развитии заболеваний человека. // Научно-практическая ревматология. — 2016. — Т. 54. — №1. — С. 60-77. [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Rheumatology Science and Practice. 2016;54(1):60-77. (In Russ.)] DOI:10.14412/1995-4484-2016-60-77</mixed-citation><mixed-citation xml:lang="en">Насонов Е.Л., Елисеев М.С. Роль интерлейкина 1 в развитии заболеваний человека. // Научно-практическая ревматология. — 2016. — Т. 54. — №1. — С. 60-77. [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Rheumatology Science and Practice. 2016;54(1):60-77. (In Russ.)] DOI:10.14412/1995-4484-2016-60-77</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">McQueen FM, Chhana A, Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies. Nat Rev Rheumatol. 2012;8(3):173-181. DOI:10.1038/nrrheum.2011.207</mixed-citation><mixed-citation xml:lang="en">McQueen FM, Chhana A, Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies. Nat Rev Rheumatol. 2012;8(3):173-181. DOI:10.1038/nrrheum.2011.207</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015;32(1):31-41. DOI:10.1007/s12325-014-0175-z</mixed-citation><mixed-citation xml:lang="en">Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015;32(1):31-41. DOI:10.1007/s12325-014-0175-z</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15(2):189-192. DOI:10.1002/art.1780150209</mixed-citation><mixed-citation xml:lang="en">Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15(2):189-192. DOI:10.1002/art.1780150209</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2):186-191. DOI:10.1097/BOR.0000000000000028</mixed-citation><mixed-citation xml:lang="en">Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2):186-191. DOI:10.1097/BOR.0000000000000028</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Campion EW, Glynn RJ, Delabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med. 1987;82(3):421-426. DOI:10.1016/0002-9343(87)90441-4</mixed-citation><mixed-citation xml:lang="en">Campion EW, Glynn RJ, Delabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med. 1987;82(3):421-426. DOI:10.1016/0002-9343(87)90441-4</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shiozawa A, Szabo SM, Bolzani A, et al. Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. J Rheumatol. 2017;44(3):388-396. DOI:10.3899/jrheum.160452</mixed-citation><mixed-citation xml:lang="en">Shiozawa A, Szabo SM, Bolzani A, et al. Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. J Rheumatol. 2017;44(3):388-396. DOI:10.3899/jrheum.160452</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018;77(7):1048-1052. DOI:10.1136/annrheumdis-2017-212288</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018;77(7):1048-1052. DOI:10.1136/annrheumdis-2017-212288</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zuo T, Liu X, Jiang L, et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Dis. 2016;16(1). DOI:10.1186/s12872-016-0379-z</mixed-citation><mixed-citation xml:lang="en">Zuo T, Liu X, Jiang L, et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Dis. 2016;16(1). DOI:10.1186/s12872-016-0379-z</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">White J, Sofat R, Hemani G, et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2016;4(4):327-336. DOI:10.1016/s2213-8587(15)00386-1</mixed-citation><mixed-citation xml:lang="en">White J, Sofat R, Hemani G, et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2016;4(4):327-336. DOI:10.1016/s2213-8587(15)00386-1</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеева М.Е., Елисеев М.С. Значение гиперурикемии в развитии заболеваний человека и методы ее коррекции. // Доктор.Ру. — 2019. — №2. — С. 47-54. [Eliseeva ME, Eliseev MS. The Role of Hyperuricemia in Human Morbidity, and Treatment Options. Doctor.Ru. 2019;(2):47-54. (In Russ.)] DOI:10.31550/1727-2378-2019-157-2-47-54</mixed-citation><mixed-citation xml:lang="en">Елисеева М.Е., Елисеев М.С. Значение гиперурикемии в развитии заболеваний человека и методы ее коррекции. // Доктор.Ру. — 2019. — №2. — С. 47-54. [Eliseeva ME, Eliseev MS. The Role of Hyperuricemia in Human Morbidity, and Treatment Options. Doctor.Ru. 2019;(2):47-54. (In Russ.)] DOI:10.31550/1727-2378-2019-157-2-47-54</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592-1600. DOI:10.1136/annrheumdis-2019-215933</mixed-citation><mixed-citation xml:lang="en">Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592-1600. DOI:10.1136/annrheumdis-2019-215933</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheumatol. 2015;67(10):2557-2568. DOI:10.1002/art.39254</mixed-citation><mixed-citation xml:lang="en">Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheumatol. 2015;67(10):2557-2568. DOI:10.1002/art.39254</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Roddy E, Choi HK. Epidemiology of Gout. Rheum Dis Clin North Am. 2014;40(2):155-175. DOI:10.1016/j.rdc.2014.01.001</mixed-citation><mixed-citation xml:lang="en">Roddy E, Choi HK. Epidemiology of Gout. Rheum Dis Clin North Am. 2014;40(2):155-175. DOI:10.1016/j.rdc.2014.01.001</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141. DOI:10.1002/art.30520</mixed-citation><mixed-citation xml:lang="en">Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141. DOI:10.1002/art.30520</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-662. DOI:10.1038/nrrheum.2015.91</mixed-citation><mixed-citation xml:lang="en">Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-662. DOI:10.1038/nrrheum.2015.91</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 2005;64(2):267-272. DOI:10.1136/ard.2004.024091</mixed-citation><mixed-citation xml:lang="en">Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 2005;64(2):267-272. DOI:10.1136/ard.2004.024091</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hyndman D, Liu S, Miner JN. Urate Handling in the Human Body. Curr Rheumatol Rep. 2016;18(6):34. DOI:10.1007/s11926-016-0587-7</mixed-citation><mixed-citation xml:lang="en">Hyndman D, Liu S, Miner JN. Urate Handling in the Human Body. Curr Rheumatol Rep. 2016;18(6):34. DOI:10.1007/s11926-016-0587-7</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, House ME, Gamble GD, et al. Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge. Arthritis Res Ther. 2014;16(1):R34. DOI:10.1186/ar4463</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, House ME, Gamble GD, et al. Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge. Arthritis Res Ther. 2014;16(1):R34. DOI:10.1186/ar4463</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review. BMC Musculoskelet Disord. 2015;16:296. DOI:10.1186/s12891-015-0762-4</mixed-citation><mixed-citation xml:lang="en">Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review. BMC Musculoskelet Disord. 2015;16:296. DOI:10.1186/s12891-015-0762-4</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-38. DOI:10.1136/annrheumdis-2019-215315</mixed-citation><mixed-citation xml:lang="en">Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-38. DOI:10.1136/annrheumdis-2019-215315</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446. DOI:10.1002/acr.21772</mixed-citation><mixed-citation xml:lang="en">Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446. DOI:10.1002/acr.21772</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС. Подагра. В кн.: Ревматология. Российские клинические рекомендации. / Под ред. Насонова Е.Л. — М.: ГЭОТАР-Медиа; 2017. — С. 253-264. [Eliseev MS. Podagra. In: Nasovnov EL, editor. Revmatologiya. Russian clinical guidelines. Moscow: GEOTAR-Media; 2017. p. 253-264. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Елисеев МС. Подагра. В кн.: Ревматология. Российские клинические рекомендации. / Под ред. Насонова Е.Л. — М.: ГЭОТАР-Медиа; 2017. — С. 253-264. [Eliseev MS. Podagra. In: Nasovnov EL, editor. Revmatologiya. Russian clinical guidelines. Moscow: GEOTAR-Media; 2017. p. 253-264. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309-312. DOI:10.1136/bmj.39449.819271.BE</mixed-citation><mixed-citation xml:lang="en">Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309-312. DOI:10.1136/bmj.39449.819271.BE</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Барскова В.Г., Елисеев М.С., Насонова В.А., Насонов Е.Л. Алкоголь и клиническая картина у больных подагрой. // Современная ревматология. — 2007. — Т. 1. — №1. — С. 37-42. [Barskova VG, Yeliseyev MS, Nasonova VA, Nasonov YL. Аlcohol and the clinical picture of gout. Sovremennaia revmatologiia. 2007;1(1):37-42. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Барскова В.Г., Елисеев М.С., Насонова В.А., Насонов Е.Л. Алкоголь и клиническая картина у больных подагрой. // Современная ревматология. — 2007. — Т. 1. — №1. — С. 37-42. [Barskova VG, Yeliseyev MS, Nasonova VA, Nasonov YL. Аlcohol and the clinical picture of gout. Sovremennaia revmatologiia. 2007;1(1):37-42. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210-216. DOI:10.1097/BOR.0b013e32835d951e</mixed-citation><mixed-citation xml:lang="en">Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210-216. DOI:10.1097/BOR.0b013e32835d951e</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Dessein PH, Shipton EA, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59(7):539-543. DOI:10.1136/ard.59.7.539</mixed-citation><mixed-citation xml:lang="en">Dessein PH, Shipton EA, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59(7):539-543. DOI:10.1136/ard.59.7.539</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73(5):797-802. DOI:10.1136/annrheumdis-2013-203970</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73(5):797-802. DOI:10.1136/annrheumdis-2013-203970</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Yamashita S, Matsuzawa Y, Tokunaga K, et al. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes. 1986;10(4):255-264.</mixed-citation><mixed-citation xml:lang="en">Yamashita S, Matsuzawa Y, Tokunaga K, et al. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes. 1986;10(4):255-264.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Serpa Neto A, Rossi FM, Valle LG, et al. Relation of uric acid with components of metabolic syndrome before and after Roux-en-Y gastric bypass in morbidly obese subjects. Arq Bras Endocrinol Metabol. 2011;55(1):38-45. DOI:10.1590/s0004-27302011000100005</mixed-citation><mixed-citation xml:lang="en">Serpa Neto A, Rossi FM, Valle LG, et al. Relation of uric acid with components of metabolic syndrome before and after Roux-en-Y gastric bypass in morbidly obese subjects. Arq Bras Endocrinol Metabol. 2011;55(1):38-45. DOI:10.1590/s0004-27302011000100005</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115. DOI:10.1002/art.22466</mixed-citation><mixed-citation xml:lang="en">Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115. DOI:10.1002/art.22466</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-689. DOI:10.2337/diacare.24.4.683</mixed-citation><mixed-citation xml:lang="en">Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-689. DOI:10.2337/diacare.24.4.683</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ротарь О.П., Либис Р.А., Исаева Е.Н., и др. Распространенность метаболического синдрома в разных городах РФ. // Российский кардиологический журнал. — 2012. — Т. 17. — №2. — С. 55-62. [Rotar OP, Libis RA, Isaeva EN, et al. Metabolic syndrome prevalence in Russian cities. Russian Journal of Cardiology. 2012;17(2):55-62. (In Russ.)] DOI:10.15829/1560-4071-2017-8-82-89</mixed-citation><mixed-citation xml:lang="en">Ротарь О.П., Либис Р.А., Исаева Е.Н., и др. Распространенность метаболического синдрома в разных городах РФ. // Российский кардиологический журнал. — 2012. — Т. 17. — №2. — С. 55-62. [Rotar OP, Libis RA, Isaeva EN, et al. Metabolic syndrome prevalence in Russian cities. Russian Journal of Cardiology. 2012;17(2):55-62. (In Russ.)] DOI:10.15829/1560-4071-2017-8-82-89</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Kim TH, Lee SS, Yoo JH, et al. The relationship between the regional abdominal adipose tissue distribution and the serum uric acid levels in people with type 2 diabetes mellitus. Diabetol Metab Syndr. 2012;4(1):3. DOI:10.1186/1758-5996-4-3</mixed-citation><mixed-citation xml:lang="en">Kim TH, Lee SS, Yoo JH, et al. The relationship between the regional abdominal adipose tissue distribution and the serum uric acid levels in people with type 2 diabetes mellitus. Diabetol Metab Syndr. 2012;4(1):3. DOI:10.1186/1758-5996-4-3</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Vuolteenaho K, Koskinen A, Moilanen E. Leptin - a link between obesity and osteoarthritis. applications for prevention and treatment. Basic Clin Pharmacol Toxicol. 2014;114(1):103-108. DOI:10.1111/bcpt.12160</mixed-citation><mixed-citation xml:lang="en">Vuolteenaho K, Koskinen A, Moilanen E. Leptin - a link between obesity and osteoarthritis. applications for prevention and treatment. Basic Clin Pharmacol Toxicol. 2014;114(1):103-108. DOI:10.1111/bcpt.12160</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Quinones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268(1 Pt 1):E1-5. DOI:10.1152/ajpendo.1995.268.1.E1</mixed-citation><mixed-citation xml:lang="en">Quinones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268(1 Pt 1):E1-5. DOI:10.1152/ajpendo.1995.268.1.E1</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Huang J, Sun Y, Niu K, et al. Does elevated serum uric acid level predict the hypertension incidence? A Chinese prospective cohort study. Clin Exp Hypertens. 2015;37(6):498-504. DOI:10.3109/10641963.2015.1013121</mixed-citation><mixed-citation xml:lang="en">Huang J, Sun Y, Niu K, et al. Does elevated serum uric acid level predict the hypertension incidence? A Chinese prospective cohort study. Clin Exp Hypertens. 2015;37(6):498-504. DOI:10.3109/10641963.2015.1013121</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Ma LD, Sun RX, Xin Y, et al. Clinical characteristics in gout patients with different body mass index. Zhonghua Nei Ke Za Zhi. 2017;56(5):353-357. DOI:10.3760/cma.j.issn.0578-1426.2017.05.010</mixed-citation><mixed-citation xml:lang="en">Ma LD, Sun RX, Xin Y, et al. Clinical characteristics in gout patients with different body mass index. Zhonghua Nei Ke Za Zhi. 2017;56(5):353-357. DOI:10.3760/cma.j.issn.0578-1426.2017.05.010</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Барскова В.Г., Елисеев М.С., Зилов А.В., Насонов Е.Л. Влияние гипергликемии и гиперинсулинемии на уровень мочевой кислоты и течение артрита у больных подагрой с сахарным диабетом 2 типа. // Ожирение и метаболизм. — 2007. — Т. 4. — №1. — С. 19-23. [Barskova VG, Eliseev MS, Zilov AV, Nasonov EL. Vliyanie giperglikemii i giperinsulinemii na uroven’ mochevoy kisloty i techenie artrita u bol’nykh podagroy s sakharnym diabetom 2 tipa. Obesity and metabolism. 2007;4(1):19-23 (In Russ.)] DOI:10.14341/2071-8713-4908</mixed-citation><mixed-citation xml:lang="en">Барскова В.Г., Елисеев М.С., Зилов А.В., Насонов Е.Л. Влияние гипергликемии и гиперинсулинемии на уровень мочевой кислоты и течение артрита у больных подагрой с сахарным диабетом 2 типа. // Ожирение и метаболизм. — 2007. — Т. 4. — №1. — С. 19-23. [Barskova VG, Eliseev MS, Zilov AV, Nasonov EL. Vliyanie giperglikemii i giperinsulinemii na uroven’ mochevoy kisloty i techenie artrita u bol’nykh podagroy s sakharnym diabetom 2 tipa. Obesity and metabolism. 2007;4(1):19-23 (In Russ.)] DOI:10.14341/2071-8713-4908</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев М.С., Барскова В.Г., Ильиных Е.В., Насонова В.А. Синдром инсулинорезистентности и подагра: исторический аспект и современное состояние проблемы. // Клиническая геронтология. — 2005. — Т. 11. — №4. — С. 30-41. [Eliseev MS, Barskova VG, Il’inykh EV. Sindrom insulinorezistentnosti i podagra: istoricheskiy aspekt i sovremennoe sostoyanie problemy. Klinicheskaia gerontologiia. 2005;11(4):30-41. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Елисеев М.С., Барскова В.Г., Ильиных Е.В., Насонова В.А. Синдром инсулинорезистентности и подагра: исторический аспект и современное состояние проблемы. // Клиническая геронтология. — 2005. — Т. 11. — №4. — С. 30-41. [Eliseev MS, Barskova VG, Il’inykh EV. Sindrom insulinorezistentnosti i podagra: istoricheskiy aspekt i sovremennoe sostoyanie problemy. Klinicheskaia gerontologiia. 2005;11(4):30-41. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев М.С., Барскова В.Г., Денисов И.С. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). // Терапевтический архив. — 2015. — Т. 87. — №5. — С. 10-15. [Eliseev MS, Barskova VG, Denisov IS. Time course of changes in the clinical manifestations of gout in men: Data of a 7-year retrospective follow-up. Ter Arkh.2015;87(5):10-15. (In Russ.)] DOI:10.17116/terarkh201587510-15</mixed-citation><mixed-citation xml:lang="en">Елисеев М.С., Барскова В.Г., Денисов И.С. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). // Терапевтический архив. — 2015. — Т. 87. — №5. — С. 10-15. [Eliseev MS, Barskova VG, Denisov IS. Time course of changes in the clinical manifestations of gout in men: Data of a 7-year retrospective follow-up. Ter Arkh.2015;87(5):10-15. (In Russ.)] DOI:10.17116/terarkh201587510-15</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Ellmann H, Bayat S, Araujo E, et al. Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits. Arthritis Rheumatol. 2020;72(1):150-156. DOI:10.1002/art.41063</mixed-citation><mixed-citation xml:lang="en">Ellmann H, Bayat S, Araujo E, et al. Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits. Arthritis Rheumatol. 2020;72(1):150-156. DOI:10.1002/art.41063</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Nielsen SM, Bartels EM, Henriksen M, et al. OP0340 Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal observational studies. Ann Rheum Dis. 2017;76(Suppl 2):191-196. DOI:10.1136/annrheumdis-2017-eular.2651</mixed-citation><mixed-citation xml:lang="en">Nielsen SM, Bartels EM, Henriksen M, et al. OP0340 Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal observational studies. Ann Rheum Dis. 2017;76(Suppl 2):191-196. DOI:10.1136/annrheumdis-2017-eular.2651</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Singh M. Mood, food, and obesity. Front Psychol. 2014;5. DOI:10.3389/fpsyg.2014.00925</mixed-citation><mixed-citation xml:lang="en">Singh M. Mood, food, and obesity. Front Psychol. 2014;5. DOI:10.3389/fpsyg.2014.00925</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Treatment of obesity: drugs and surgery. In: Powers PS. Obesity: the regulation of weight. Baltimore: Williams &amp; Wilkins; 1980. p. 325-389.</mixed-citation><mixed-citation xml:lang="en">Treatment of obesity: drugs and surgery. In: Powers PS. Obesity: the regulation of weight. Baltimore: Williams &amp; Wilkins; 1980. p. 325-389.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Sjöström L, Lindroos AK, Peltonen M. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. J Vasc Surg. 2005;41(5):911. DOI:10.1016/j.jvs.2005.02.005</mixed-citation><mixed-citation xml:lang="en">Sjöström L, Lindroos AK, Peltonen M. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. J Vasc Surg. 2005;41(5):911. DOI:10.1016/j.jvs.2005.02.005</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Lenz M, Richter T, Mühlhauser I. The Morbidity and Mortality Associated With Overweight and Obesity in Adulthood. Dtsch Arztebl Int. 2009. DOI:10.3238/arztebl.2009.0641</mixed-citation><mixed-citation xml:lang="en">Lenz M, Richter T, Mühlhauser I. The Morbidity and Mortality Associated With Overweight and Obesity in Adulthood. Dtsch Arztebl Int. 2009. DOI:10.3238/arztebl.2009.0641</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery. Jama. 2004;292(14):1724. DOI:10.1001/jama.292.14.1724</mixed-citation><mixed-citation xml:lang="en">Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery. Jama. 2004;292(14):1724. DOI:10.1001/jama.292.14.1724</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Шестакова М.В., и др. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-ий пересмотр (лечение морбидного ожирения у взрослых). // Ожирение и метаболизм. — 2018. — Т. 15. — №1. — С. 53-70. [Dedov II, Melnichenko GA, Shestakova MV, et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and metabolism. 2018;15(1):53-70. (In Russ.)] DOI:10.14341/OMET2018153-70</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Мельниченко Г.А., Шестакова М.В., и др. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-ий пересмотр (лечение морбидного ожирения у взрослых). // Ожирение и метаболизм. — 2018. — Т. 15. — №1. — С. 53-70. [Dedov II, Melnichenko GA, Shestakova MV, et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and metabolism. 2018;15(1):53-70. (In Russ.)] DOI:10.14341/OMET2018153-70</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European Guidelines on metabolic and bariatric surgery. Obes Facts. 2013;6(5):449-468. DOI:10.1159/000355480</mixed-citation><mixed-citation xml:lang="en">Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European Guidelines on metabolic and bariatric surgery. Obes Facts. 2013;6(5):449-468. DOI:10.1159/000355480</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">O’Brien PE, Dixon JB, Laurie C, et al. Treatment of Mild to Moderate Obesity with Laparoscopic Adjustable Gastric Banding or an Intensive Medical Program. Ann Intern Med. 2006;144(9):625. DOI:10.7326/0003-4819-144-9-200605020-00005</mixed-citation><mixed-citation xml:lang="en">O’Brien PE, Dixon JB, Laurie C, et al. Treatment of Mild to Moderate Obesity with Laparoscopic Adjustable Gastric Banding or an Intensive Medical Program. Ann Intern Med. 2006;144(9):625. DOI:10.7326/0003-4819-144-9-200605020-00005</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Facchini F. Relationship Between Resistance to Insulin-Mediated Glucose Uptake, Urinary Uric Acid Clearance, and Plasma Uric Acid Concentration. Jama. 1991;266(21):3008. DOI:10.1001/jama.1991.03470210076036</mixed-citation><mixed-citation xml:lang="en">Facchini F. Relationship Between Resistance to Insulin-Mediated Glucose Uptake, Urinary Uric Acid Clearance, and Plasma Uric Acid Concentration. Jama. 1991;266(21):3008. DOI:10.1001/jama.1991.03470210076036</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Richette P, Poitou C, Manivet P, et al. Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients. Arthritis Care Res (Hoboken). 2016;68(7):1036-1042. DOI:10.1002/acr.22798</mixed-citation><mixed-citation xml:lang="en">Richette P, Poitou C, Manivet P, et al. Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients. Arthritis Care Res (Hoboken). 2016;68(7):1036-1042. DOI:10.1002/acr.22798</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Tana C, Busetto L, Di Vincenzo A, et al. Management of hyperuricemia and gout in obese patients undergoing bariatric surgery. Postgrad Med. 2018;130(6):523-535. DOI:10.1080/00325481.2018.1485444</mixed-citation><mixed-citation xml:lang="en">Tana C, Busetto L, Di Vincenzo A, et al. Management of hyperuricemia and gout in obese patients undergoing bariatric surgery. Postgrad Med. 2018;130(6):523-535. DOI:10.1080/00325481.2018.1485444</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Pool B, Yip S, et al. Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: a prospective study. Ann Rheum Dis. 2013;72(9):1583-1584. DOI:10.1136/annrheumdis-2013-203545</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Pool B, Yip S, et al. Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: a prospective study. Ann Rheum Dis. 2013;72(9):1583-1584. DOI:10.1136/annrheumdis-2013-203545</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739-2748. DOI:10.1161/CIRCULATIONAHA.112.122556</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739-2748. DOI:10.1161/CIRCULATIONAHA.112.122556</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Maglio C, Peltonen M, Neovius M, et al. Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial. Ann Rheum Dis. 2017;76(4):688-693. DOI:10.1136/annrheumdis-2016-209958</mixed-citation><mixed-citation xml:lang="en">Maglio C, Peltonen M, Neovius M, et al. Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial. Ann Rheum Dis. 2017;76(4):688-693. DOI:10.1136/annrheumdis-2016-209958</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1301-1311. DOI:10.1136/ard.2006.055251</mixed-citation><mixed-citation xml:lang="en">Zhang W. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1301-1311. DOI:10.1136/ard.2006.055251</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Паневин Т.С., Елисеев М.С., Шестакова М.В., Насонов Е.Л. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2 типа у пациентов с сахарным диабетом 2 типа в сочетании с гиперурикемией и подагрой. // Терапевтический архив. — 2020. — Т. 92. — №5. — С. 110-118. [Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Ter Arkh. 2020;92(5):110-118. (In Russ.)] DOI:10.26442/00403660.2020.05.000633</mixed-citation><mixed-citation xml:lang="en">Паневин Т.С., Елисеев М.С., Шестакова М.В., Насонов Е.Л. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2 типа у пациентов с сахарным диабетом 2 типа в сочетании с гиперурикемией и подагрой. // Терапевтический архив. — 2020. — Т. 92. — №5. — С. 110-118. [Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Ter Arkh. 2020;92(5):110-118. (In Russ.)] DOI:10.26442/00403660.2020.05.000633</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Herman J, Goldbourt U. Uric Acid and Diabetes: Observations in a Population Study. Lancet. 1982;320(8292):240-243. DOI:10.1016/s0140-6736(82)90324-5</mixed-citation><mixed-citation xml:lang="en">Herman J, Goldbourt U. Uric Acid and Diabetes: Observations in a Population Study. Lancet. 1982;320(8292):240-243. DOI:10.1016/s0140-6736(82)90324-5</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Richette P, Poitou C, Garnero P, et al. 005 Benefits of Massive Weight Loss on Symptoms, Systemic Inflammation and Cartilage Turnover in Obese Patientswith Knee Osteoarthritis. Osteoarthritis Cartilage. 2010;18:S11. DOI:10.1016/s1063-4584(10)60032-5</mixed-citation><mixed-citation xml:lang="en">Richette P, Poitou C, Garnero P, et al. 005 Benefits of Massive Weight Loss on Symptoms, Systemic Inflammation and Cartilage Turnover in Obese Patientswith Knee Osteoarthritis. Osteoarthritis Cartilage. 2010;18:S11. DOI:10.1016/s1063-4584(10)60032-5</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Menenakos E, Doulami G, Tzanetakou IP, et al. The Use of Serum Uric Acid Concentration as an Indicator of Laparoscopic Sleeve Gastrectomy Success. Int Surg. 2015;100(1):173-179. DOI:10.9738/intsurg-d-13-00186.1</mixed-citation><mixed-citation xml:lang="en">Menenakos E, Doulami G, Tzanetakou IP, et al. The Use of Serum Uric Acid Concentration as an Indicator of Laparoscopic Sleeve Gastrectomy Success. Int Surg. 2015;100(1):173-179. DOI:10.9738/intsurg-d-13-00186.1</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Craig MH, Poole GV, Hauser CJ. Postsurgical gout. Am Surg. 1995;61(1):56-59.</mixed-citation><mixed-citation xml:lang="en">Craig MH, Poole GV, Hauser CJ. Postsurgical gout. Am Surg. 1995;61(1):56-59.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Antozzi P, Soto F, Arias F, et al. Development of Acute Gouty Attack in the Morbidly Obese Population after Bariatric Surgery. Obes Surg. 2005;15(3):405-407. DOI:10.1381/0960892053576802</mixed-citation><mixed-citation xml:lang="en">Antozzi P, Soto F, Arias F, et al. Development of Acute Gouty Attack in the Morbidly Obese Population after Bariatric Surgery. Obes Surg. 2005;15(3):405-407. DOI:10.1381/0960892053576802</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Friedman JE, Dallal RM, Lord JL. Gouty attacks occur frequently in postoperative gastric bypass patients. Surg Obes Relat Dis. 2008;4(1):11-13. DOI:10.1016/j.soard.2007.09.012</mixed-citation><mixed-citation xml:lang="en">Friedman JE, Dallal RM, Lord JL. Gouty attacks occur frequently in postoperative gastric bypass patients. Surg Obes Relat Dis. 2008;4(1):11-13. DOI:10.1016/j.soard.2007.09.012</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Romero-Talamas H, Daigle CR, Aminian A, et al. The effect of bariatric surgery on gout: a comparative study. Surg Obes Relat Dis. 2014;10(6):1161-1165. DOI:10.1016/j.soard.2014.02.025</mixed-citation><mixed-citation xml:lang="en">Romero-Talamas H, Daigle CR, Aminian A, et al. The effect of bariatric surgery on gout: a comparative study. Surg Obes Relat Dis. 2014;10(6):1161-1165. DOI:10.1016/j.soard.2014.02.025</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Katsogridaki G, Tzovaras G, Sioka E, et al. Hyperuricemia and acute gout after laparoscopic sleeve gastrectomy. Clin Obes. 2019;9(2):e12296. DOI:10.1111/cob.12296</mixed-citation><mixed-citation xml:lang="en">Katsogridaki G, Tzovaras G, Sioka E, et al. Hyperuricemia and acute gout after laparoscopic sleeve gastrectomy. Clin Obes. 2019;9(2):e12296. DOI:10.1111/cob.12296</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Чикина М.Н. Профилактика приступов артрита при назначении уратснижающей терапии у больных подагрой. // Научно-практическая ревматология. — 2018. — Т. 56. — №6. — С. 760-766. [Chikina MN. Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout. Rheumatology Science and Practice. 2018;56(6):760-766. (In Russ.)] DOI:10.14412/1995-4484-2018-760-766</mixed-citation><mixed-citation xml:lang="en">Чикина М.Н. Профилактика приступов артрита при назначении уратснижающей терапии у больных подагрой. // Научно-практическая ревматология. — 2018. — Т. 56. — №6. — С. 760-766. [Chikina MN. Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout. Rheumatology Science and Practice. 2018;56(6):760-766. (In Russ.)] DOI:10.14412/1995-4484-2018-760-766</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Busetto L, Marangon M, De Stefano F. High-protein low-carbohydrate diets: what is the rationale? Diabetes Metab Res Rev. 2011;27(3):230-232. DOI:10.1002/dmrr.1171</mixed-citation><mixed-citation xml:lang="en">Busetto L, Marangon M, De Stefano F. High-protein low-carbohydrate diets: what is the rationale? Diabetes Metab Res Rev. 2011;27(3):230-232. DOI:10.1002/dmrr.1171</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Busetto L, Dicker D, Azran C, et al. Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management. Obes Facts. 2017;10(6):597-632. DOI:10.1159/000481825</mixed-citation><mixed-citation xml:lang="en">Busetto L, Dicker D, Azran C, et al. Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management. Obes Facts. 2017;10(6):597-632. DOI:10.1159/000481825</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Кушнаренко Н.Н., Мишко М.Ю., Медведева Т.А., Кушнаренко К.Е. Случай развития хронической тофусной подагры у пациента с морбидным ожирением после лапароскопического регулируемого бандажирования желудка. // Ожирение и метаболизм. — 2020. — Т. 17. — №1. — C. 93-99. [Kushnarenko NN, Mishko MY, Medvedeva TA, Kushnarenko KE. A case of chronic tophi gout in morbidly obese patient after laparoscopic adjustable gastric banding. Obesity and metabolism. 2020;17(1):93-99. (In Russ.)] DOI:10.14341/omet9736</mixed-citation><mixed-citation xml:lang="en">Кушнаренко Н.Н., Мишко М.Ю., Медведева Т.А., Кушнаренко К.Е. Случай развития хронической тофусной подагры у пациента с морбидным ожирением после лапароскопического регулируемого бандажирования желудка. // Ожирение и метаболизм. — 2020. — Т. 17. — №1. — C. 93-99. [Kushnarenko NN, Mishko MY, Medvedeva TA, Kushnarenko KE. A case of chronic tophi gout in morbidly obese patient after laparoscopic adjustable gastric banding. Obesity and metabolism. 2020;17(1):93-99. (In Russ.)] DOI:10.14341/omet9736</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
